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Abstract
Aim of the study: Biliary tract cancer is a rare tumor characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival.. 
Methods: Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analyzed. A prognostic model defining 3 prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centers.
Results: Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) as compared to patients with non-resectable tumors (9.1 months; n=329, P<0.0001). Based on univariable and multivariable analyses of clinical data a prognostic model was created using variables available before treatment. Those were age, metastasis, c-reactive protein (CRP), international normalized ratio (INR), and bilirubin. The prognostic score distinguished three groups with a median OS of 21.8, 8.6 and 2.6 months, respectively. The validation cohort had a median OS of 20.2, 14.0 and 6.5 months, respectively. The prognostic impact of the score was independent of the tumor site and of treatment procedures. 
Conclusions: Here, we identified prognostic factors and propose a prognostic score to estimate survival, which can be applied to all patients independent of tumor site and before initial treatment. Further valdiation in prospective trials is required.
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Biliary tract cancer (BTC) is a rare and aggressive malignancy.  It comprises intra- and extrahepatic cholangiocarcinoma (ICCA and ECCA) and gallbladder cancer (GC).  ECCA is divided into perihilar cholangiocarcinoma (CCA) and distal CCA. The incidence in western countries increases up to 1/ 100.000 per year (1;2). Radical resection is the only curative treatment. However, high rates of non-resectable tumors and recurrence after resection result in poor prognosis. The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is widely used for staging of BTC (3). In patients not eligible for resection, the use of TNM is limited, because in this situation, T and N state can only be defined clinically/ radiologically. Furthermore, clinicopathological data beyond TNM may be useful to predict outcome more reliably. Therefore, alternative staging systems, prognostic scores and nomograms for BTC have been established by different groups (4-15). Using histological details as vascular invasion or tumor diameter, most are only applicable to resected patients. Only a few staging systems have been developed in a preoperative setting or for patients with advanced disease (6;7). Very recently, a set of prognostic criteria for outcome in unresectable BTC has been developed from patients included in the ABC-02 study, which was validated in patietns that participated in ten international clinical studies.  White blood cells, haemoglobin, disease status, bilirubin, neurophils, gender and performance status were considered prognostic for survival in these patients with advanced disease, which were eligible for clinical trials (19).   Our study comprises a large patient cohort with BTC, in which clinical, histopathological and laboratory data were collected at time of first diagnosis. We aimed to identify independent risk factors and to establish a prognosis score that would be applicable for clinical use before treatment in patients with resectable and non-resectable tumours. Furthermore, we aimed to validate the score in a large independent patient cohort of four different institutions in Germany.

Patients
We reviewed 569 patients with BTC treated at Medical School Hannover from 2000 to 2010 for the analysis of prognostic factors and to establish a prognostic score. We included patients with intrahepatic CCA (ICCA), extrahepatic CCA (ECCA), gallbladder carcinoma (GC).  Patients with mixed CCA/ hepatocellular carcinoma (CCA/HCC) were excluded. The diagnosis was histologically proven either by resection or by biopsy in patients with advanced disease. The local registration offices provided survival data. To complete treatment data, primary care physicians and oncologists were systematically interrogated by a questionnaire. Patients were followed until death or June 2013. All recorded laboratory values with normal ranges are listed in the supplementary methods (online only). To validate the score in an independent cohort of patients, we applied it to 557 patients with CCA The validation cohort includes the following patients: 40 patients with advanced BTC treated in the Department of Medical Oncology and Hematology, Charité, Berlin, from 2001 to 2011. 57 patients treated from 2004 to 2012 in the Department of Internal Medicine 1, University of Bonn, Germany. 192 patients treated in Hannover Medical School from 2011 to 2013, 268 patients treated in University of Mainz from 1999 to 2016. The study was approved by the local ethics committee.

Statistical analysis
Comparisons of characteristics were performed with the use of the chi-square test for categorical variables and ANOVA for continuous variables. The Kaplan–Meier method and the log rank test were used to calculate and compare survival rates. To estimate the hazard ratios (HR) and 95% confidence intervals (CI) for the adjusted survival analysis a Cox proportional-hazards model was used. The association of clinical, histological and laboratory factors with survival, was assessed in separate univariate and multivariate Cox regression analyses. The identified factors were thereafter included in a final multivariable model with stepwise backward elimination. Although continuous, all biochemical factors were used as categorical variables by defining cutoff values in the Cox models for ease of interpretation of the HRs. A two-sided P <0.05 was considered to be statistically significant.

Development and validation of a prognostic score
The original dataset of 569 BTC patients was used as a ‘training set. The linear predictor (xb) is split at the Cox cut-points i.e. 50 and 85th percentiles (based on the training set) to generate three risk groups ranging from low to high (score 1 to 3). The discriminatory performance of the model was assessed visually via Kaplan-Meier (KM) plots. Model performance was evaluated by application to the validation set. Evidence of deviation from proportional hazards assumption was assessed using Stata’s phtest and the appropriateness of the covariate functional forms have been checked with the aid of Martingale residuals.




Original patient cohort 
In the original patient set, we included 569 patients. Survival data were available for 562 patients (98.8%). Median overall survival (OS) was 14.5 months for all patients. Median follow up was 14 months, ranging from 10 days to 12.8 years. Mean age was 60 years and 57.4% were male (Table 1). Most patients were diagnosed with ICCA, representing 55.3% of all patients (N=315) , followed by ECCA (N=162), GC (N=92). The survival curves of the different tumor sites are shown in Figure 1A and survival rates in supplemental table S1 (online only).

Effect of surgery on survival
Figure 1B illustrates the applied treatments. Of all patients 57.2% of patients (N=325) were initially considered for resection. R0- or R1-resection was achieved in 37.4% (N=213), in 6.2% (N=35), tumor remained macroscopically (R2) and 13% (N=75) were shown to be not resectable during surgical exploration. Outcome was significantly better in resected patients compared to non-resected patients (23.9 vs. 9.1 months median OS; P<0.0001). Median OS after R2 resection was significantly worse compared to R0- or R1 resection (8.5 months vs. 27 and 21.1 months, respectively, P<0.0001, Figure 1C) and compared to exploratory laparotomy without any resection (11.9 months, P=0.028).  Interestingly, about half of all patients with R2 status were patients with GC (17/35, 48.6%), whereas the largest group of intraoperatively unresectable patients were patients with ECCA (34/75, 45.3%).  About 83/3% of R2 resected ptients and 80/1% of intraoperatively unresectable patients were treated subsequently with CT.  In both groups, one patients died within the first month after laparotomy.. Tumor stage according to UICC discriminated well between different risk groups in resected patients (Figure 1D). 21.1% (N=44) of all R0- and R1 resected patients who survived the first 60 days after resection obtained adjuvant (R0) or additive (R1) treatment. 90.9% of these were treated with gemcitabine. There was a non-significant trend towards a better survival in the treatment group (median OS 30.6 vs. 26.9 months, P=0.55).

Outcome of patients with advanced disease
The majority of patients were not eligible for curative treatment. At first diagnosis, metastasis was present in 38%, being a strong predictor of a poor outcome (HR 2.1; CI 1.7 to 2.8; P<0.0001). Of 332 non-resectable patients and 254 patients with recurrent disease, chemotherapy (CT) data of 324 patients were available. Non-resectable patients receiving CT had a significantly longer survival compared to patients receiving best supportive care only (12.7 vs. 2.4 months P<0.0001). The median OS of all patients (including patients with recurrent disease) after start of CT was 10.2 months. As first line CT, 57.4% received gemcitabine as single agent and 16.4% combined with a platinum (cisplatin 8.9%, oxaliplatin 7.4%). About 14.8% were treated with a fluoropyrimidine based therapy.  Patients with GC with first-line CT had a significantly shorter survival than patients with ECCA or ICCA (9.3 months vs 9.8 months and 11.3 months respectively; p=.02 and .02; Figure S2). 

Validation cohort
The validation cohort consisted of 557 patients from four German institutions with a median follow up of 14.7 months, ranging from 0.3 to 163.9 months. The mean age was 54 years, mean OS was 16.6 months. The distribution of tumor sites was significantly different from that of the original cohort (p<0.0001). In the validation cohort, there were more GC (38.8 vs 15.7%) and less ECCA (10.8 vs 27.6%). About 48.8% had ICCA. The occurrence of metastases at time of diagnosis was more frequent in the validation group (47.4% vs 39%, p=0.001). Nevertheless, patients of the validation more often than in the original cohort underwent resection, 53.5% vs 37.8%, p<0.0001. This may explain the significantly better median OS of 16.6 months in the validation group vs. 14.5 months in the original group (p=0.035). 

Prognostic factors
Detailed results of univariate analysis of clinical characteristics and laboratory results are listed in Table 2. In multivariate analysis, age of more than 60 years, the presence of metastases, liver cirrhosis, resection or surgical exploration only, an elevation of bilirubin to more than 55µmol/L , or C-reactive protein (CRP) to more than 3mg/L, leukocytosis, and an elevation of INR to more than 1.25 were significantly associated with the outcome (Table 3). 

Development and validation of a prognostic score
A prognostic score using the following five factors independent of surgical was established: age, metastatic disease, bilirubin, CRP, INR (Figure 2A). For the score, the biochemistry factors were used as continuous variables for more precise results. 
The factor ‘cirrhosis’ was not considered for the score, as we cannot formally exclude cirrhosis in all patients without liver biopsy. To generate three risk groups ranging from low to high (score 1 to 3), the cut-points generated were xb ≤-0.75 (score 1),>-0.75 to ≤0.3 (score 2), >0.3 (score 3). The model showed no evidence of deviation from proportional hazards assumption. The appropriateness of the covariate functional forms was confirmed with the aid of Martingale residuals. The parameters of the model are shown table 4. 
The equation of the linear predictor (xb) was:

xb = (1.110 x metastasis) + (0.436 x log10 CRP) + (-0.848 x (1/INR3)) + (0.299 x log10 bilirubin) + (-0.069 x age) + (0.0007 x age2)
Where absence of metastases=0, presence of metastases =1

Calculating the above, then applying the cut-points allocates each patient into one of three risk groups (Figure 2a). The median OS of patients in the three groups was 21.8, 8.6 and 2.6 months, respectively. A calculator of the score can be found online (S2).

Validation of the score 
Next, we validated the score by applying it to the validation cohort of 557 patients, revealing a median OS of 20.2, 14.0 and 6.5 months, respectively (Figure 2B). The difference between the prognostic groups (1 vs 2 and 2 vs 3) was significant, respectively.
Finally, the score was calculated for the different tumor sites and for resected vs. non-resected patients in all patients to confirm that its use is independent of tumor location and treatment procedures. In all different groups, score 1-3 discriminated patients with a good, intermediate and poor survival (Figure 3). 

Discussion 
BTC is a rare and aggressive malignancy and prospective data are scarce. By defining common prognostic variables in patients with BTC of different primary sites, we were able to establish a prognostic scoring system to estimate survival prior to any treatment procedures. Its validity was shown in a second cohort of patients. 
The intention of our score is to provide a tool for classifying patients according to their risk to die of BTC as assessed at the time of diagnosis. Among the heterogeneous group of patients with BTC, there are those who profit from radical treatment and those who do not profit from cancer treatment at all. It is important to objectify this risk in the individual patient in order to plan the extent and aggressiveness of the treatment. Using the score may help to identify the patients with a better prognosis or with a very poor prognosis. Thus, while patients with a score of 1 will probably benefit from radical treatment, the prognosis of patients with a score of 3 is very limited. In these patients, aggressive treatment will probably not be appropriate and best supportive care should be considered as the best treatment. Importantly, we could show that the score is applicable in ICCA, ECCA, GC and in resectable /non-resectable patients.
One strength of our study in contrast to other scores is that we validated the score in an independent patient cohort. The validation cohort contained patients from four different centers in Germany and was of about equal size as the original cohort. Moreover our population was not biased by inclusion ceriteria of clinical trials. Given the retrospective nature of this study, the cohorts differed in distribution of the tumor sites, tumor stage, resection rates and outcome. 
In contrast to existing staging systems and prognostic scores, our proposed score is the only score not only being independent from resection but also applicable to patients with BTC of different primary sites.  Although BTCs are heterogeneous, the medical treatment is substantially the same.  This is reflected by the observation that the recently published Phase II and III studies of advanced biliary cancer include all different tumour sites (21-23), providing rationale to summarize all patients with BTC and not to investigate one special tumour site in our study as well.  Not only in advanced tumours but also studies investigating the adjuvant treatment in resectable BTC, the ongoing or recently finished III trials include ICCA, ECCA, and GC. .Another advantage of our score is that all clinical and laboratory variables are available at diagnosis and thus wil be applicable to all patients with BTC without any exception. For daily clinical praxis, we provide a linke to a calculator of the score (online material).  Here we show that markers of systemic Inflammation like CRP, e.g. used in the Glasgow Prognosis Score are known to influence survival in CCA (6;13;18-22). Also, Bilirubin (5;19;24) and metastasis (24) have been previously described as prognostic in CCA and used in scores. 

Currently, there are three staging systems used: The TNM system, the staging system of the National Cancer Center of Japan (NJ) and the Liver Cancer Study Group of Japan (LCSGJ). The validity of the TNM system has been improved since the 7th edition (7;9;12). The 6th edition was criticized because it applied the staging system for HCC to CCA. In particular, tumor size was insufficient to discriminate between different tumor stages (9;32). For NJ and LCSGJ, the staging systems of Okabayashi and Yamasaki (both established for mass forming ICCA) were adopted, respectively (10;14). Both studies base only on small number of patients. Blechacz et al. concluded that none of the existing staging systems fulfills the criteria of an optimal staging system (32). Recently, the LCSGJ proposed a new staging system for mass forming ICCA based on retrospective data of 223 patients (33). This score remains to be vaildated. 
In contrast to existing staging systems and prognostic scores (5-8;11-13;34), the HPS is the only score not only beeing indepent from resection, but also applicable to patients with CCA of different primary sites. Although CCAs are very heterogeneous, the medical treatment is substantially the same (35). This is reflected by the observation that the very few recently published phase II and III-studies of biliary cancer include all different tumor sites (36-38), providing rationale to summarize all patients with CCA and not to investigate one special tumor site in our study as well. Another advantage of the HPS is, that all clinical and laboratory variables are available at diagnosis and thus will be applicable to all patients with CCA without any exception. For daily clinical praxis, we provide a link to a calculator of the HPS (online material).
In conclusion, our analysis provides detailed information about patients with BTC and describes the outcome after different treatments. With the proposed score, we offer a tool to estimate prognosis in patients with BTC at time of diagnosis, independent of tumor site and operability. In particular, in those patients with a poor prognosis, the score may help to decide that best supportive care is the treatment of choice. Additionally, the score might be used in clinical trials to stratify patient populations. Prospective studies are required for further confirmation of the applicability of the score.
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Figure 1: A: Survival of patients with Cholangiocarcinoma according to tumor site, irrespective of treatment. B: Treatment strategies applied to the primary patient cohort. C: Survival of patients depending on the result of resection. R0, microscopic tumor-free margins; R1, microscopic residual disease; R2, macroscopic residual disease; exploration: surgical exploration without resection in case of locally advanced, non-resectable disease; no surgery: patients who did not undergo surgical treatment due to advanced disease or bad performance status. D: Survival of resected patients according to UICC staging system 6th edition. ICCA, intrahepatic cholangiocarcinoma; ECCA, extrahepatic cholangiocarcinoma; GC, gallbladder carcinoma; CCA/HCC, mixed cholangiocarcinoma and hepatocellular carcinoma. 

Figure 2: (A): Survival rates of the orginal patient cohort with a score of 1-3. (B): Survival rates of the validation patient cohort with a score of 1-3.

Figure 3: Survival rates according to score 1 to 3 calculated for all patients (A), patients with intrahepatic cholangiocarcinoma (ICCA), (B), extrahepatic CCA (ECCA), (C), gallbladder carcinoma (GC), and for patients who underwent resection (D) or not (E). 
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